Tirzepatide is a dual GLP-1 and GIP receptor agonist offering significant benefits for glycemic control and weight management. It is administered weekly via subcutaneous injection, with dosing guidelines typically recommending a gradual increase over several weeks to optimize tolerance and efficacy.
- Dual GLP-1 and GIP receptor agonist.
- Administered once weekly via subcutaneous injection.
- Effective for glycemic control and significant weight reduction.
- Gradual dose escalation typically used to minimize side effects.
- Has a ~5-day half-life supporting weekly dosing.
Reconstitution
Vial strength
15 mg
Bacteriostatic water
2 mL
Concentration
7.5 mg/mL
1 unit = 0.01 mL = 75 mcg
- 1Draw 2.0 mL of bacteriostatic water using a sterile syringe.
- 2Inject the water slowly down the inside wall of the Tirzepatide vial; avoid creating foam.
- 3Gently swirl or roll the vial until the powder is completely dissolved (do not shake).
- 4Label the vial with the reconstitution date and store it in the refrigerator at 2–8 °C (35.6–46.4 °F), away from light.
- 5Utilize the reconstituted solution within 28 days.
Dosing schedule
| Phase | Dose | On a U-100 syringe |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 33 units (0.33 mL) |
| Weeks 5–8 | 5 mg | 67 units (0.67 mL) |
| Weeks 9–12 | 7.5 mg | 100 units (1.0 mL) |
| Weeks 13–16 | 10 mg | 67 units (0.67 mL) × 2 injections |
Protocol detail
| Start | Begin with 2.5 mg once weekly for the initial 4 weeks to establish an initiation dose. |
|---|---|
| Escalate | Increase the dose by 2.5 mg every 4 weeks if well-tolerated. |
| Maintenance | Adjust to a weekly dose between 5–15 mg based on the individual's response and tolerability. |
| Frequency | Administer once per week via subcutaneous injection, dedicating the same day each week for administration. |
Overview at a glance
| Goal | Support glycemic control, weight management, and metabolic health through dual incretin receptor activation. |
|---|---|
| Schedule | Weekly subcutaneous injection on the same day each week for 12–16+ weeks. |
| Dose Range | 2.5–15 mg weekly with 4-week titration intervals. |
| Reconstitution | 2.0 mL per 15 mg vial (7.5 mg/mL) for manageable injection volumes. |
| Storage | Lyophilized form stored frozen; reconstituted solution refrigerated for up to 28 days. |
How it works
Tirzepatide functions as a unique dual agonist, activating both the GLP-1 and GIP receptors. This dual action enhances insulin secretion in a glucose-dependent manner, reduces glucagon release, delays gastric emptying, and promotes a feeling of fullness by influencing appetite regulation in the brain. The combined GIP activity appears to boost metabolic advantages beyond those offered by GLP-1 agonists alone, leading to improved glycemic control and notable weight loss observed in studies. Its prolonged half-life of approximately five days facilitates convenient once-weekly dosing.
Reported effects
- Significant reduction in HbA1c for type 2 diabetes.
- Substantial body-weight loss, often exceeding GLP-1 receptor agonist comparators.
- Potential improvements in lipid profiles and blood pressure observed in some studies.
Reported side effects
- Gastrointestinal issues (nausea, diarrhea, vomiting, constipation) – typically mild to moderate and dose-dependent.
- Injection-site reactions (mild redness or irritation).
Storage
Lyophilised (unmixed)
Store at -20 °C (-4 °F) in dry, dark conditions; minimize moisture exposure. Allow to reach room temperature before opening.
After reconstitution
Refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 28 days.
Supplies
| Peptide vials | Typically 2-7 vials for an 8-16 week protocol, depending on the titration schedule. |
|---|---|
| Insulin Syringes (U-100, 1 mL) | 8-20 syringes for an 8-16 week protocol, based on weekly injection frequency. |
| Bacteriostatic Water (10 mL bottles) | 1-2 bottles suffice for a 8-16 week protocol, using 2.0 mL per 15 mg vial. |
| Alcohol Swabs | A 100-count box is recommended for any protocol length to cover vial stoppers and injection sites. |
Important notes
- Always use new, sterile insulin syringes and dispose of them properly in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to prevent local irritation.
- For doses requiring multiple injections, administer consecutively at different sites.
- Inject slowly and document your weekly dose, date, and injection site for consistency.
- Gastrointestinal side effects are common initially, but gradual dose titration helps minimize them.
Frequently asked questions
How does Tirzepatide differ from other GLP-1 medications?
Tirzepatide is unique because it is a dual agonist, activating both GLP-1 and GIP receptors. This combined action often leads to more pronounced effects on blood sugar control and weight loss compared to medications that only target the GLP-1 receptor.
What should I do if I experience side effects like nausea or diarrhea?
Gastrointestinal side effects are common, especially when starting or increasing the dose. These are typically mild to moderate and can often be managed by adhering to the gradual dose titration schedule. Rotating injection sites and staying hydrated can also help. If severe or persistent, consult a healthcare professional.
Can I adjust my dose more quickly if I feel well?
The recommended protocol involves increasing the dose every four weeks to allow your body to adjust and minimize potential side effects. Deviating from this gradual escalation without professional guidance is not advised, as it may increase the risk and severity of adverse reactions.
How should I store Tirzepatide after I mix it with water?
Once reconstituted with bacteriostatic water, Tirzepatide should be stored in the refrigerator at 2–8 °C (35.6–46.4 °F) and protected from light. It is crucial to use the solution within 28 days of reconstitution to maintain its potency and safety.
Educational reference only. These figures summarise how Tirzepatide is commonly described in research literature and supplier documentation, including the Tirzepatide listing at peptidesuk4u.co.uk. They are not a prescription, not medical advice, and not a recommendation to self-administer anything.
Related protocols
Tirzepatide (10 mg Vial)
Dual incretin agonist for glycemic control and weight management.
Tirzepatide (20 mg Vial)
Dual agonist for glucose control and weight management.
Tirzepatide (30 mg Vial)
Dual GLP-1/GIP agonist for glycemic control and weight management.
Tirzepatide (40 mg Vial)
Dual GLP-1/GIP agonist for glycemic control and weight management.